{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2892","statisticalComment":"stratified by age group and region","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.713","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.208","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.928","statisticalComment":"stratified by age group and region","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7"},{"groupId":"OG001","value":"54.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"210"}],"units":"Participants"}],"description":"Overall survival was defined as the time (days) from date of randomization to date of death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Since the median value could not be estimated due to censored data, the percentage of participants who died is presented.","groups":[{"description":"Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle","id":"OG000","title":"Sorafenib (Nexavar, BAY43-9006)"},{"description":"Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS)","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until the database cut-off (30 AUG 2017), study duration approximately eight years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}